ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 94 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,869,191 | -44.3% | 1,105,309 | 0.0% | 2.34% | -32.6% |
| Q2 2023 | $10,533,595 | +68.3% | 1,105,309 | +94.2% | 3.47% | +34.7% |
| Q1 2023 | $6,259,451 | -25.7% | 569,041 | 0.0% | 2.58% | -29.6% |
| Q4 2022 | $8,421,807 | -22.6% | 569,041 | 0.0% | 3.66% | -7.9% |
| Q3 2022 | $10,874,000 | -10.3% | 569,041 | 0.0% | 3.97% | -34.9% |
| Q2 2022 | $12,126,000 | +10.6% | 569,041 | 0.0% | 6.11% | +17.8% |
| Q1 2022 | $10,960,000 | -7.1% | 569,041 | 0.0% | 5.19% | +5.1% |
| Q4 2021 | $11,802,000 | -13.2% | 569,041 | 0.0% | 4.94% | +2.7% |
| Q3 2021 | $13,594,000 | -12.5% | 569,041 | 0.0% | 4.80% | -21.5% |
| Q2 2021 | $15,529,000 | -5.7% | 569,041 | 0.0% | 6.12% | +15.9% |
| Q1 2021 | $16,462,000 | -12.9% | 569,041 | -15.3% | 5.28% | -15.2% |
| Q4 2020 | $18,895,000 | – | 671,716 | – | 6.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,434,232 | $162,443,000 | 13.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76,641,000 | 7.44% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,960,000 | 5.19% |
| Logos Global Management LP | 1,500,000 | $28,890,000 | 3.75% |
| Omega Fund Management, LLC | 623,836 | $12,015,000 | 2.46% |
| Orbimed Advisors | 6,073,850 | $116,982,000 | 1.90% |
| MPM BioImpact LLC | 258,500 | $4,979,000 | 1.34% |
| 1492 Capital Management LLC | 75,192 | $1,448,000 | 0.77% |
| SECTORAL ASSET MANAGEMENT INC | 219,136 | $4,221,000 | 0.75% |
| EcoR1 Capital, LLC | 895,503 | $17,247,000 | 0.54% |